×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

 

LEADERSHIP

Senior Management
  • Victoria Blatter
    Victoria H. Blatter
    Senior Vice President, U.S. Government Affairs
  • Robert Bradway
    Robert A. Bradway
    Chairman and Chief Executive Officer
  • Judy Gawlik Brown
    Judy Gawlik Brown
    Senior Vice President, Corporate Affairs
  • Tia Bush
    Tia Bush
    Senior Vice President, Quality
  • Raymond Deshaies
    Senior Vice President, Global Research
  • Steven Galson
    Steven K. Galson
    Senior Vice President, Global Regulatory Affairs and Safety
  • Murdo Gordon
    Murdo Gordon
    Executive Vice President, Global Commercial Operations
  • Jonathan Graham
    Jonathan Graham
    Executive Vice President, General Counsel and Secretary
  • Peter Griffith
    Executive Vice President and Chief Financial Officer
  • Lori Johnston
    Executive Vice President, Human Resources
  • Corinne Legoff
    Corinne M. Le Goff
    Senior Vice President, General Manager, U.S. General Medicine
  • Elliott Levy
    Elliott M. Levy
    Senior Vice President, Global Development
  • Marrache Gilles
    Gilles Marrache
    Senior Vice President, Regional General Manager
  • David Meline
    David W. Meline
    Executive Vice President, Finance
  • Jerry Murry
    Jerry Murry
    Senior Vice President, Process Development
  • Mike Nohaile
    Mike Nohaile
    Senior Vice President, Strategy, Commercialization & Innovation
  • Cynthia Patton
    Cynthia M. Patton
    Senior Vice President and Chief Compliance Officer
  • Arleen Paulino
    Arleen Paulino
    Senior Vice President, Manufacturing
  • David Piacquad
    David A. Piacquad
    Senior Vice President, Business Development
  • Annalisa Pizzarello
    Annalisa Pizzarello
    Senior Vice President, Results Delivery Office
  • David Reese
    David M. Reese
    Executive Vice President, Research and Development
  • Esteban Santos
    Esteban Santos
    Executive Vice President, Operations
  • Darryl Sleep
    Darryl Sleep
    Senior Vice President, Global Medical and Chief Medical Officer
  • Susan Sweeney  SVP, Global Product Strategy and Commercial Innovation
    Susan Sweeney
    Senior Vice President, Global Product Strategy and Commercial Innovation
  • Ian Thompson
    Ian Thompson
    Senior Vice President, Regional General Manager
  • Mike Zahigian
    Mike Zahigian
    Senior Vice President and Chief Information Officer
Board of Directors
  • Wanda M. Austin

    Retired President and Chief Executive Officer, The Aerospace Corporation

    Wanda M. Austin is the retired President and Chief Executive Officer of The Aerospace Corporation, a leading architect of the United States’ national security space programs, where she served from 2008 until her retirement in 2016. From 2004 to 2007, Dr. Austin was Senior Vice President, National Systems Group of The Aerospace Corporation. Dr. Austin joined The Aerospace Corporation in 1979 and served in various positions from 1979 until 2004.

    Dr. Austin served as Interim President of the University of Southern California from August 2018 until June 2019. She has served as an Adjunct Research Professor at the University of Southern California’s Viterbi School of Engineering since 2007. She is the co-founder of MakingSpace, Inc., where she serves as a motivational speaker on STEM education. Dr. Austin has been a director of Chevron Corporation, a petroleum, exploration, production and refining company, since 2016, serving on its Board Nominating and Governance Committee and chairing its Public Policy Committee. Dr. Austin has been a director of Virgin Galactic Holdings, Inc., a commercial space flight company, since October 2019 and is a member of its Audit Committee and Safety Committee, and chair of its Compensation Committee. Dr. Austin is a trustee of the University of Southern California and previously served on the boards of directors of the National Geographic Society and the Space Foundation. Dr. Austin received an undergraduate degree from Franklin & Marshall College, a master’s degree from the University of Pittsburgh, and a doctorate from the University of Southern California. She is a member of the National Academy of Engineering.

  • Robert A. Bradway

    Chairman and Chief Executive Officer, Amgen Inc.

    Robert A. Bradway is Amgen's chairman and chief executive officer. Bradway became chairman in January 2013 and chief executive officer in May 2012. Bradway served as the company's president and chief operating officer from May 2010 to May 2012, and was appointed to the Amgen Board of Directors in October 2011. He joined the company in 2006 as vice president, Operations Strategy, and served as executive vice president and chief financial officer from April 2007 to May 2010.

    Prior to joining Amgen, he was a managing director at Morgan Stanley in London where, beginning in 2001, he had responsibility for the firm's banking department and corporate finance activities in Europe. Bradway joined Morgan Stanley in New York as a health care industry investment banker in 1985 and moved to London in 1990.

    He is a member of the board of directors of The Boeing Company, serving on its Audit and Finance committees. Bradway serves on the board of trustees of the University of Southern California and on the advisory board of the Leonard D. Schaeffer Center for Health Policy and Economics at that university. He is the chairman of the CEO Roundtable on Cancer, a non-profit organization comprised of executives founded to bring solutions to cancer treatment and prevention. He is a member of the American Heart Association CEO Roundtable, which is helping the Association meet its goal of improving the cardiovascular health of all Americans. Bradway is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA) board of directors.

    Bradway holds a bachelor's degree in biology from Amherst College and a master's degree in business administration from Harvard University.

  • Brian J. Druker

    Physician-Scientist and Professor of Medicine, Oregon Health & Science University; Director of the OHSU Knight Cancer Institute and JELD-WEN Chair of Leukemia Research; Associate Dean for Oncology, OHSU School of Medicine

    Brian J. Druker joined Oregon Health & Science University, or OHSU, in 1993 and is currently a physician-scientist and professor of medicine. Dr. Druker has served as the director of the OHSU Knight Cancer Institute since 2007, associate dean for oncology of the OHSU School of Medicine since 2010, and the JELD-WEN chair of leukemia research at OHSU since 2001. He was an investigator with the Howard Hughes Medical Institute, a nonprofit medical research organization, from 2002 to 2019.

    Dr. Druker has served on the scientific advisory board of Aptose Biosciences Inc., a biotechnology company, since 2013. Dr. Druker was on the scientific advisory board of Grail, Inc., a biotechnology company, from 2016 to 2019. In 2011, he founded Blueprint Medicines Corporation, a biopharmaceutical company, and remains as a scientific advisor to this company. In 2006, he founded MolecularMD, a privately-held molecular diagnostics company that was acquired by ICON plc in 2019. Dr. Druker has received numerous awards, including the Lasker-DeBakey Clinical Research Award in 2009, the Japan Prize in Healthcare and Medical Technology in 2012, the Albany Medical Center Prize in 2013, and the Sjöberg Prize in 2019, for influential work in the development of STI571 (Gleevec®) for the treatment of chronic myeloid leukemia. He was elected to the National Academy of Sciences in 2012 as well as the National Academy of Medicine in 2007. Dr. Druker received both an undergraduate degree and his doctorate from the University of California, San Diego.

  • Robert A. Eckert  (Lead Independent Director)

    Chairman Emeritus, Mattel, Inc.

    Robert A. Eckert has been an Operating Partner at Friedman Fleischer & Lowe, a private equity firm, since 2014. Mr. Eckert was the Chief Executive Officer of Mattel, Inc., a toy design, manufacture and marketing company, having held this position from 2000 through 2011, and its Chairman of the Board from 2000 through 2012. He was President and Chief Executive Officer of Kraft Foods Inc., a consumer packaged food and beverage company, from 1997 to 2000, Group Vice President from 1995 to 1997, President of the Oscar Mayer Foods Division from 1993 to 1995 and held various other senior executive and other positions from 1977 to 1992.

    Mr. Eckert has been a director of McDonald’s Corporation, a company which franchises and operates McDonald’s restaurants in the global restaurant industry, since 2003, serving as the Chair of the Public Policy and Strategy Committee and a member of the Executive and Governance Committees. Mr. Eckert also has served as a director of Levi Strauss & Co., a jeans and casual wear manufacturer, since 2010, serving as Chair of the Compensation Committee and a member of the Nominating, Governance and Corporate Citizenship Committee. Levi Strauss & Co. was a privately-held company until March 2019 when it became publicly traded. In March 2020, Mr. Eckert was appointed a director of Uber Technologies, Inc., a personal mobility, meal delivery and logistics technology platform, serving on its Compensation and Nominating and Governance Committees. Mr. Eckert was a director of Smart & Final Stores, Inc., a warehouse store, from 2013 until 2014 prior to it becoming a publicly-traded company. He was appointed director of Eyemart Express Holdings LLC, a privately-held eyewear retailer and portfolio company of Friedman Fleischer & Lowe, in 2015. Mr. Eckert is on the Global Advisory Board of the Kellogg School of Management at Northwestern University and serves on the Eller College National Board of Advisors at the University of Arizona. Mr. Eckert received an undergraduate degree from the University of Arizona and a master’s degree in business administration from the Kellogg School of Management at Northwestern University.

  • Greg C. Garland

    Chairman and Chief Executive Officer, Phillips 66

    Greg C. Garland is the Chairman and Chief Executive Officer of Phillips 66, a diversified energy manufacturing and logistics company created through the repositioning of ConocoPhillips, having held this position since 2012. Mr. Garland chairs the Executive Committee of Phillips 66. Prior to Phillips 66, Mr. Garland served as Senior Vice President, Exploration and Production, Americas of ConocoPhillips from 2010 to 2012. He was President and Chief Executive Officer of Chevron Phillips Chemical Company (now a joint venture between Phillips 66 and Chevron) from 2008 to 2010 and Senior Vice President, Planning and Specialty Chemicals from 2000 to 2008. Mr. Garland served in various positions at Phillips Petroleum Company from 1980 to 2000. Mr. Garland is a member of the Engineering Advisory Council for Texas A&M University. Mr. Garland received an undergraduate degree from Texas A&M University.

  • Fred Hassan

    Director, Warburg Pincus LLC

    Fred Hassan is Director at Warburg Pincus LLC, a global private equity investment institution, since 2018. Mr. Hassan was Special Limited Partner at Warburg Pincus LLC from 2017 to 2018 and Partner and Managing Director from 2011 to 2017 and, prior to that, served as Senior Advisor from 2009 to 2010. Mr. Hassan was Chairman of the Board and Chief Executive Officer of Schering-Plough Corporation from 2003 to 2009. Prior to this, Mr. Hassan was Chairman, President and Chief Executive Officer of Pharmacia Corporation, from 2001 to 2003. Before assuming these roles, he had served as President and Chief Executive Officer of Pharmacia Corporation from its creation in 2000 as a result of the merger of Pharmacia & Upjohn, Inc. with Monsanto Company. He was President and Chief Executive Officer of Pharmacia & Upjohn, Inc. beginning in 1997. Mr. Hassan previously held senior positions with Wyeth (formerly known as American Home Products), including that of Executive Vice President with responsibility for its pharmaceutical and medical products businesses, and served as a member of the board from 1995 to 1997. Prior to that, Mr. Hassan held various roles at Sandoz Pharmaceuticals and headed its U.S. pharmaceuticals businesses.

    Mr. Hassan has been a director of Precigen, Inc. (formerly Intrexon Corporation), a biotechnology company, since 2016, serving on its Compensation Committee. Mr. Hassan was a director of Time Warner Inc., a media company, from 2009 until its acquisition by AT&T Inc., a provider of communications and digital entertainment services, in 2018.  Mr. Hassan was a director of Avon Products, Inc., a manufacturer and marketer of beauty and related products, from 1999 until 2013 and served on its Compensation and Management Development, Nominating and Corporate Governance and Audit Committees, as lead independent director from 2009 to 2012, and Chairman of the Board between January and April 2013. Mr. Hassan was Chairman of the Board of Bausch & Lomb, from 2010 until its acquisition by Valeant Pharmaceuticals International, Inc., a pharmaceutical company, in 2013. Mr. Hassan served on the board of directors and the Compensation and Audit Committees of Valeant Pharmaceuticals International, Inc. from 2013 to 2014. Mr. Hassan received an undergraduate degree from Imperial College of Science and Technology, University of London and a master’s degree in business administration from Harvard Business School.

  • Charles M. Holley, Jr.

    Former Executive Vice President and Chief Financial Officer of Wal-Mart Stores, Inc.

    Charles M. Holley, Jr. is the former Executive Vice President and Chief Financial Officer for Wal-Mart Stores, Inc., or Walmart, where he served from 2010 to 2015 and as Executive Vice President in January 2016. Prior to this, Mr. Holley served as Executive Vice President, Finance and Treasurer of Walmart from 2007 to 2010. From 2005 to 2006, he served as Senior Vice President. Prior to that, Mr. Holley was Senior Vice President and Controller from 2003 to 2005. Mr. Holley served various roles in Wal-Mart International from 1994 through 2002. Prior to this, Mr. Holley served in various roles at Tandy Corporation. He spent more than ten years with Ernst & Young LLP. Mr. Holley was an Independent Senior Advisor, U.S. CFO Program, at Deloitte LLP, a privately-held provider of audit, consulting, tax, and advisory services, from 2016 to 2019.

    Mr. Holley has been a director of Phillips 66, an energy manufacturing and logistics company, since October 2019 and serves on the Audit and Finance, and Public Policy Committees. In connection with the 2020 spin-off from United Technologies Corporation of Carrier Global Corporation, a provider of heating, ventilating, air conditioning (HVAC), refrigeration, fire, and security solutions, Mr. Holley has been appointed as a director of Carrier. He serves on the Advisory Council for the McCombs School of Business at the University of Texas at Austin and the University of Texas Presidents’ Development.

  • Tyler Jacks

    David H. Koch Professor of Biology, Massachusetts Institute of Technology and Director of the David H. Koch Institute for Integrative Cancer Research

    Tyler Jacks joined the faculty of Massachusetts Institute of Technology, or MIT, in 1992 and is currently the David H. Koch Professor of Biology and director of the David H. Koch Institute for Integrative Cancer Research, which brings together biologists and engineers to improve detection, diagnosis and treatment of cancer, a position he has held since 2007. Dr. Jacks has been an investigator with the Howard Hughes Medical Institute, a nonprofit medical research organization, since 1994.

    Dr. Jacks has been a director of Thermo Fisher Scientific, Inc., a life sciences supply company, since 2009, serving on its Strategy and Finance Committee and scientific advisory board and chairing its Science and Technology Committee. In 2006, he co-founded T2 Biosystems, Inc., a biotechnology company, and served on its scientific advisory board until 2013. Dr. Jacks has served on the scientific advisory board of SQZ Biotech, a privately-held biotechnology company, since 2015. Dr. Jacks served on the scientific advisory board of Aveo Pharmaceuticals Inc., a biopharmaceutical company, from 2001 until 2013. In 2015, Dr. Jacks founded Dragonfly Therapeutics, Inc., a privately-held biopharmaceutical company, and serves as Chair of its scientific advisory board. He was appointed to the National Cancer Advisory Board, which advises and assists the Director of the National Cancer Institute with respect to the National Cancer Program, in 2011 and served as Chair until 2016. In 2016, Dr. Jacks was named to a blue ribbon panel of scientists and advisors established as a working group of the National Cancer Advisory Board and served as co-Chair advising the Cancer MoonshotSM Task Force. Dr. Jacks was a director of MIT's Center for Cancer Research from 2001 to 2007 and received numerous awards including the Paul Marks Prize for Cancer Research and the American Association for Cancer Research Award for Outstanding Achievement. He was elected to the National Academy of Sciences as well as the National Academy of Medicine in 2009 and received the MIT Killian Faculty Achievement Award in 2015. Dr. Jacks received an undergraduate degree from Harvard University and his doctorate from the University of California, San Francisco.

  • Ellen J. Kullman

    President and Chief Executive Officer of Carbon, Inc.

    Ellen J. Kullman was appointed President and Chief Executive Officer of Carbon, Inc., or Carbon, a privately-held 3D printing company, in November 2019, and has served as a director of Carbon since 2016. She is the former President, Chair and Chief Executive Officer of E.I. du Pont de Nemours and Company, or DuPont, a science and technology-based company, where she served from 2009 to 2015. Prior to this, Ms. Kullman served as President of DuPont from 2008 to 2009. From 2006 through 2008, she served as Executive Vice President of DuPont. Prior to that, Ms. Kullman was Group Vice President, DuPont Safety and Protection. Ms. Kullman has been a director of Goldman Sachs Group, Inc., an investment banking firm, since 2016, serving on its Compensation, Corporate Governance and Nominating, and Risk Committees. Ms. Kullman has been a director of Dell Technologies, a technology company, since 2016, serving on its Audit and Capital Stock Committees. Ms. Kullman served as a director of United Technologies Corporation, a technology products and services company, from 2011 (and as lead director from 2018) until April 2020, serving on its Compensation, Finance and Executive Committees. Ms. Kullman served as a director of General Motors, from 2004 to 2008, serving on its Audit Committee.

    Ms. Kullman has served on the Board of Trustees of Northwestern University since 2016 and on the Board of Overseers of Tufts University School of Engineering since 2006. She served as Chair of the US-China Business Council from 2013 to 2015. In 2016, Ms. Kullman joined the Temasek Americas Advisory Panel of Temasek Holdings (Private) Limited, a privately-held investment company based in Singapore. Ms. Kullman received a bachelor of science in mechanical engineering degree from Tufts University and a master’s degree from the Kellogg School of Management at Northwestern University.

  • Ronald D. Sugar

    Chairman Emeritus, Northrop Grumman Corporation

    Ronald D. Sugar is the retired Chairman of the Board and Chief Executive Officer of Northrop Grumman Corporation, a global aerospace and defense company, having held these posts from 2003 through 2009.

    Dr. Sugar has been a director of Chevron Corporation, a petroleum, exploration, production and refining company, since 2005, serving as the lead director and on the Management Compensation Committee and chairing the Board Nominating and Governance Committee. Dr. Sugar has been a director of Apple Inc., a manufacturer and seller of, among other things, personal computers, mobile communication and media devices, since 2010, chairing the Audit and Finance Committee. Dr. Sugar has been a director of Uber Technologies, Inc., a personal mobility, meal delivery and logistics technology platform, since 2018, serving as the Chair of the board of directors and chairing the Nominating and Governance Committee and serving on the Compensation Committee. Dr. Sugar served as a director of Air Lease Corporation, an aircraft leasing company, from 2010 until May 2020, chairing the Compensation Committee and serving on the Nominating and Corporate Governance Committee. Since 2010, he has been a senior advisor to Ares Management LLC, a privately-held asset manager and registered investment advisor. In 2014, Dr. Sugar joined the Temasek Americas Advisory Panel of Temasek Holdings (Private) Limited, a privately-held investment company based in Singapore. Dr. Sugar is a member of the National Academy of Engineering, trustee of the University of Southern California, member of the UCLA Anderson School of Management Board of Advisors, and director of the Los Angeles Philharmonic Association.

  • R. Sanders Williams

    President Emeritus of Gladstone Institutes. Professor of Medicine, University of California, San Francisco and Professor of Medicine, Duke University

    R. Sanders Williams is the President Emeritus of Gladstone Institutes, a non-profit biomedical research enterprise, having served in this position since 2018, and was the Chief Executive Officer of Gladstone Foundation, a not-for-profit organization supporting the Gladstone Institutes during 2018. Dr. Williams has been a Professor of Medicine at the University of California, San Francisco since 2010, and Professor of Medicine at Duke University since 2018. Dr. Williams was both President of Gladstone Institutes and its Robert W. and Linda L. Mahley Distinguished Professor of Medicine, from 2010 to 2017. Prior to this, Dr. Williams served as Senior Vice Chancellor of the Duke University School of Medicine from 2008 to 2010 and Dean of the Duke University School of Medicine from 2001 to 2008. He was the founding Dean of the Duke-NUS Graduate Medical School, Singapore, from 2003 to 2008 and served on its Governing Board from 2003 to 2010. From 1990 to 2001, Dr. Williams was Chief of Cardiology and Director of the Ryburn Center for Molecular Cardiology at the University of Texas, Southwestern Medical Center.

    Dr. Williams has been a director of the Laboratory Corporation of America Holdings, a diagnostic technologies company, since 2007, serving on the Audit and Compensation Committees and chairing the Quality and Compliance Committee. Dr. Williams was a director of Bristol-Myers Squibb Company, a pharmaceutical company, from 2006 until 2013. Dr. Williams has served on the board of directors of the Gladstone Foundation, a non-profit institution that is distinct from Gladstone Institutes, since 2012 and on the board of directors of Exploratorium, a non-profit science museum and learning center located in San Francisco, from 2011 until 2018. Dr. Williams was elected to the National Academy of Medicine in 2002. Dr. Williams received his undergraduate degree from Princeton University and his doctorate from Duke University.

 

Scientific Advisory Boards

At Amgen, we recognize that innovation comes from many sources. The formation of the Amgen Scientific Advisory Boards formalizes our belief in engaging outside experts to help us theorize, test and spur our discovery and development processes forward. The Scientific Advisory Boards provide external scientific review of our research and development activities and assists management in making significant scientific judgments.

Co-Chairs

Elliott Sigal, MD, PhD
Former Chief Scientific Officer, Bristol-Myers Squibb
David Baltimore, PhD
President Emeritus and Robert Andrews Millikan Professor of Biology, California Institute of Technology

Research Trends and Emerging Technologies

David J. Anderson, PhD
California Institute of Technology, Howard Hughes Medical Institute
Ron Evans, PhD
Salk Institute, Howard Hughes Medical Institute, National Academy of Sciences, Institute of Medicine
Richard O. Hynes, PhD, FRS
Koch Institute and Department of Biology at MIT, Howard Hughes Medical Institute, Broad Institute
John Kuriyan, PhD
University of California, Berkeley, Howard Hughes Medical Institute
Diane Mathis, PhD
Harvard Medical School
Frank McCormick, PhD
University California San Francisco, Helen Diller Family Comprehensive Cancer Center
Ruslan Medzhitov, PhD
Yale University School of Medicine
Robert Tjian, PhD
Howard Hughes Medical Institute, University of California, Berkeley
Jonathan S. Weissman, PhD
Howard Hughes Medical Institute, University of California, San Francisco

Cardiovascular and Metabolic

Alfred L. George, Jr., MD
Northwestern University, Feinberg School of Medicine
David Alan Kass, MD
The Johns Hopkins University School of Medicine
Daniel P. Kelly, MD
Perelman School of Medicine, University of Pennsylvania
Peter Libby, MD
Harvard Medical School, Brigham and Women's Hospital, Division of Cardiovascular Medicine
Elizabeth McNally, MD, PhD
Northwestern University, Feinberg School of Medicine
Jeff D. Molkentin, PhD
Cincinnati Children's Hospital Medical Center
Thomas Quertermous, MD
William G. Irwin Professor of Medicine, Stanford University
Marlene Rabinovitch, MD
Stanford School of Medicine
Alan R. Tall MB, BS
Tilden-Weger-Bieler Professor of Medicine, Head of the Division of Molecular Medicine, Columbia University
Gordon Tomaselli, MD
The Johns Hopkins University School of Medicine

Oncology

James P Allison, PhD
MD Anderson Cancer Center
Mark M. Davis, PhD
Stanford School of Medicine
Siwen Hu-Lieskovan, MD, PhD
University of Utah, School of Medicine
Dirk Jager, PhD
Managing Director, NCT Heidelberg
Robert Negrin, MD
Stanford School of Medicine
Drew Pardoll, MD, PhD
The Johns Hopkins University School of Medicine
Antoni Ribas, MD, PhD
University of California at Los Angeles Medical Center
Benoit Van den Eynde, MD, PhD
Ludwig Institute for Cancer Research, de Duve Institute, Brussels
Jedd Wolchok, MD, PhD
Memorial Sloan Kettering Cancer Center

 

×